Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hecolin Immunogenicity and Safety in HIV+/- Adults and Children
NCT06306196Phase 2Recruiting
- Sponsor
- International Vaccine Institute
- Start
- Apr 2024
- Primary completion
- Jan 2026
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of HEV 239 in hepatitis E (HEV), sponsored by International Vaccine Institute. Started Apr 2024; status: recruiting.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on NCT06306196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06306196.